Europeans OK use of Amgen's Repatha to prevent heart attacks, strokes

You are here: Home > Central Coast Health Watch > Current Article

Europeans OK use of Amgen’s Repatha to prevent heart attacks, strokes

By Staff Report / Thursday, May 17th, 2018 / Comments Off on Europeans OK use of Amgen’s Repatha to prevent heart attacks, strokes

The European Commission approved Amgen’s cardiovascular drug Repatha to reduce risk in adults with established conditions like myocardial infarction, stroke or peripheral arterial disease. The label update follows data from a Repatha outcomes study that showed a 20 percent reduction in major adverse cardiovascular events when it was combined with statin therapy, including a 27…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.